Yahoo Web Search

Search results

1. www.thelancet.com › journals › lancetTivozanib plus nivolumab versus tivozanib monotherapy in ...

   www.thelancet.com › journals › lancet

   1 day ago · From Nov 4, 2021, to June 16, 2023, 343 patients were randomly assigned to tivozanib–nivolumab (n=171) or tivozanib monotherapy (n=172). Median follow-up was 12·0 months.

2. Images

   • 
   • 
   • 
   • 

   View all

3. www.targetedonc.com › view › lenvatinibLenvatinib/Pembrolizumab Combo Shows Promise in Thymic ...

   www.targetedonc.com › view › lenvatinib

   • Cached

   1 day ago · Treatment with lenvatinib (Lenvima) plus pembrolizumab (Keytruda) demonstrated a 5-month progression-free survival (PFS) rate of almost 90% in patients with platinum refractory advanced B3-thymoma and thymic carcinoma without autoimmune disorders, according to data from the phase 2 single-arm PECATI trial (NCT04710628) presented at ESMO ...

4. www.nature.com › articles › s41571/024/00942-7New clinical trials in CUP and a novel paradigm in cancer ...

   www.nature.com › articles › s41571/024/00942-7

   3 days ago · Department of Medical Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France Elie Rassy & Fabrice André CESP, INSERM U1018, Université Paris-Saclay, Villejuif, France

5. dailyreporter.esmo.org › esmo-congress-2024Multi-gene ctDNA profiling matches pts to targeted therapies

   dailyreporter.esmo.org › esmo-congress-2024

   • Cached

   1 day ago · Results from two trials as part of a programme incorporating liquid biopsy into precision oncology workflows at the Institute Gustave Roussy, Villejuif, France, are presented at the ESMO Congress 2024 (Barcelona, 13–17 September) showing that comprehensive circulating tumour DNA (ctDNA) analysis of liquid biopsies effectively matches patients with advanced cancer to targeted therapies ...

6. www.redjournal.org › article › S0360-3016(24)03370-4Association between the regular use of vaginal dilators and ...

   www.redjournal.org › article › S0360-3016(24)03370-4

   1 day ago · 5 Department of Radiotherapy, Gustave-Roussy, Villejuif, France 6 Homi Bhabha Cancer Hospital and Research Centre, Tata Memorial Centre, Mumbai, India 7 Institute of Oncology Ljubljana, Department of Radiotherapy, Slovenia and University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

7. bmcneurol.biomedcentral.com › articles › 10Neurological hospitalisations in childhood cancer survivors ...

   bmcneurol.biomedcentral.com › articles › 10

   • Cached

   4 days ago · Purpose Childhood cancer survivors (CCS) have an increased risk of developing late chronic diseases, which can be influenced by the cancer type and its treatment. These chronic diseases can be severe and disabling, typically emerging years to decades after treatment. These deficits negatively impact quality of life, intelligence quotient, and memory. This study investigated how much the cancer ...

8. www.urotoday.com › recent-abstracts › urologicTivozanib plus nivolumab versus tivozanib monotherapy in ...

   www.urotoday.com › recent-abstracts › urologic

   • Cached

   1 day ago · Institut de Cancerologie Strasbourg Europe, Strasbourg, France Catholic University of the Sacred Heart, Milan, Italy Centre Hospitalier Universitaire de Poitiers, Poitiers, France